Evaluation of the mutagenic and genotoxic activities of anti-hepatitis B analogs of β-L-adenosine by the Ames test and the Comet assay

Antiviral Research

Volumn 50, Issue 2, 2001, Pages 139-145

  Placidi, L ^a   De Meo, M ^b   Gosselin, G ^c   Imbach, J L ^c   Bryant, M L ^d   Dumenil, G ^b   Sommadossi, J P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIV MONTPELLIER   (France)

^d Novirio Pharmaceuticals   (United States)

Author keywords

Ames test; Comet assay; Genotoxicity; Hepatitis B; Purine nucleosides

Indexed keywords

ADENOSINE DERIVATIVE; BETA 2' DEOXYADENOSINE; BETA 2',3' DIDEOXYADENOSINE; BETA ADENOSINE; UNCLASSIFIED DRUG;

AMES TEST; ANTIVIRAL ACTIVITY; ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; GENOTOXICITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; COMET ASSAY; DEOXYADENOSINES; DIDEOXYADENOSINE; HEPATITIS B; HUMANS; LYMPHOCYTES; MUTAGENICITY TESTS; MUTAGENS; SALMONELLA TYPHIMURIUM;

SALMONELLA TYPHIMURIUM; TYPHIMURIUM;

EID: 0035031809     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00140-1     Document Type: Article

References (22)

1. Ayers K.M., Clive D., Tucker W.E., Hajian G., De Miranda P. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fund. Applied Tox. 32:1996;148-158.
2. 2) not a gaussian distribution. Mutation Res. 398:1998;101-110.
3. Boyum A. Separation of leukocytes from blood and bone marrow. Scand. J. Clin. Lab. Invest. 21:(Suppl. 21):1968;77-89.
4. Bryant M.L., Bridges E.G., Placidi L., Faraj A., Loi A.G., Pierra C., Dukhan D., Gosselin G., Imbach J.L., Hernandez B., Juodawlkis A., Tennant B., Korba B., Cote P., Marion P., Cretton-Scott E., Schinazi R.F., Sommadossi J.P. Unnatural antiviral nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45:2001;229-235.
5. De Méo M.P., Laget M., Di Giorgio C., Guiraud H., Botta A., Castegnaro M., Duménil G. Optimization of the Salmonella/mammalian microsome assay for urine mutagenisis by experimental designs. Mutation Res. 340:1996;51-65.
6. El Alaoui A.M., Faraj A., Pierra C., Boudou V., Johnson R., Mathe C., Gosselin G., Korba B.E., Imbach J.L., Schinazi R.F., Sommadossi J.P. Inhibition of hepatitis B virus replication by nucleoside enantiomers of β-2′,3′-dideoxypurine analogs. Antivir. Chem. Chemother. 7:1996;276-280.
7. Eriksson, S., Nyrgen, J., 1995. Preparing dried slides. Comet Workshop, Prague.
8. Hoofnagle J.H. Therapy of viral hepatitis. Digestion. 59:1998;563-578.
9. Lee W. Drug-induced hepatotoxicity. N. Eng. J. Med. 333:1995;1118-1127.
10. Marec F., Gelbic I. High recombinant activities of three antiviral agents, adenine derivatives, in the drosophila wing spot test. Mutation Res. 311:1994;305-317.
11. Maron P.M., Ames B.N. Revised methods for the salmonella mutagenicity test. Mutation Res. 113:1983;173-215.
12. Matsuda A., Ohara Y., Kakutani T., Negishi K., Wataya Y., Hayatsu H., Ueda T. 2-(p-nitrophenyl)-2′-deoxyadenosine, a new type of mutagenic nucleoside. Nucleic Acids Res. 18:1990;1833-1838.
13. Moore M., Harrington-Brock K.M., Parker L., Doerr C.L., Hozier J.C. Genotoxicity of 2-amino-6-N-hydroxyadenine (AHA) to mouse lymphoma and CHO cells. Mutation Res. 253:1991;63-71.
14. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., McDade H. Viral dynamics in hepatitis B virus infection. Pro. Nat. Acad. Sci. 93:1996;4398-4402.
15. Oshiro Y., Piper C.E., Soelter S.G., Balwierz P.S., Garriott M.L. Genotoxic properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU). Fund. Appl. Tox. 18:1992a;491-498.
16. Oshiro Y., Guzzie P.J., Balwierz P.S., Soelter S.G., Rohrbacher E., Gad S.C. Genetic toxicology studies of an anti-AIDS drug. Tox. Lett. 60:1992b;275-280.
17. Otova B., Holy A., Votruba I., Sladka M., Bila V., Mejsnarova B., Leskovva V. Genotoxicity of purine acyclic nucleotide analogs. Folia Biol. 43:1997;225-229.
18. Placidi, L., Faraj, A., Loi, A.G., Pierra, C., Egron, D., Cretton-Scott, E., Gosselin, G., Perigaud, C., Martin, L.T., Schinazi, R.F., Imbach, J.L., el Kouni, M.H., Sommadossi, J.P., 2001. Antiviral activity and intracellular metabolism of bis(tbutylSATE) phosphotriester of β-L-2′,3′-dideoxyadenosine, a potent inhibitor of HIV and HBV replication. Antivir. Chem. Chemother., in press.
19. Shaw T., Locarnini S.A. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver. 15:1995;169-184.
20. Sherker A.H., Marion P.L. Hepadnaviruses and hepatocellular carcinoma. Annu. Rev. Microb. 45:1991;475-507.
21. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantification of low level of DNA damage in individual cells. Exp. Cell Res. 175:1988;184-187.
22. Tsai C.H., Doong S.L., Johns D.G., Driscoll J.S., Cheng Y.C. Effect of anti-HIV 2′-beta-fluoro-2′,3′-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production. Biochem. Pharmacol. 48:1994;1477-1481.